Federal Register. Guidance for industry on diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. [cited 2024 Apr 27]. Available from: https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 [cited 2025 Jan 15];145. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063.

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.

Article  CAS  PubMed  Google Scholar 

Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102:990–9.

Article  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee. 13. Older adults: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S195–207.

Tong D. SGLT2 inhibitors in patients with HFpEF: how old is too old? J Cardiovasc Aging. 2022;2:41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183: 106396.

Article  CAS  PubMed  Google Scholar 

Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64:543–52.

Article  PubMed  PubMed Central  Google Scholar 

Amioka M, Kinoshita H, Fuji Y, Nitta K, Yamane K, Shokawa T, et al. Long‐term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS‐HF study. ESC Heart Failure. 2025;12:447–55.

Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE–TIMI 58 study. Diabetes Care. 2020;43:468–75.

Article  CAS  PubMed  Google Scholar 

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age Ageing. 2019;48:859–66.

Article  PubMed  PubMed Central  Google Scholar 

Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4:e143–54.

Article  PubMed  Google Scholar 

Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, et al. Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circ Heart Fail [Internet]. 2022 [cited 2025 Jan 15];15. Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010080.

Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation. 2020;141:100–11.

Article  CAS  PubMed  Google Scholar 

Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, et al. Kidney and cardiovascular effects of canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial. Am J Kidney Dis. 2023;82:84-96.e1.

Article  CAS  PubMed  Google Scholar 

Bellary S, Barnett AH. SGLT2 inhibitors in older adults: overcoming the age barrier. Lancet Healthy Longev. 2023;4:e127–8.

Article  PubMed  Google Scholar 

Engler C, Leo M, Pfeifer B, Juchum M, Chen-Koenig D, Poelzl K, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018. BMJ Open Diabetes Res Care. 2020;8: e001279.

Article  PubMed  PubMed Central  Google Scholar 

Rigato M, Fadini GP, Avogaro A. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25:2963–9.

Article  CAS  PubMed  Google Scholar 

Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024;53:afad254.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.

Google Scholar 

The EMPA-KIDNEY Collaborative Group. empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–27.

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–60.

Article  Google Scholar 

Filippatos G, Anker SD, Butler J, Farmakis D, Ferreira JP, Gollop ND, et al. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of <scp>EMPEROR-Reduced</scp>. Eur J Heart Fail. 2022;24:2297–304.

Article  CAS  PubMed  Google Scholar 

Triposkiadis F, Xanthopoulos A, Butler J. Cardiovascular aging and heart failure. J Am Coll Cardiol. 2019;74:804–13.

Article  PubMed  Google Scholar 

Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its Assessment. GERONA. 2016;glw089.

Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab. 2021;23:682–91.

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, De Boer RA, Hernandez AF, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757–67.

Article  CAS  PubMed  Google Scholar 

Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81:2377–87.

Article  CAS  PubMed  Google Scholar 

Baigent C, Emberson Jonathan R, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801.

Article  Google Scholar 

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–54.

Article  CAS  PubMed  Google Scholar 

Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. eClinicalMedicine. 2021;41:101163.

Article  PubMed  PubMed Central  Google Scholar 

Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650–64.

Article  PubMed  PubMed Central  Google Scholar 

Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:495–502.

Article  PubMed  Google Scholar 

Rau M, Thiele K, Hartmann N-UK, Schuh A, Altiok E, Möllmann J, et al. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovasc Diabetol. 2021;20:6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

Article  CAS  PubMed  Google Scholar 

Marx N, McGuire DK, Perkovic V, Woerle H-J, Broedl UC, Von Eynatten M, et al. Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Diabetes Care. 2017;40:1144–51.

Article  PubMed